Effective May 16, 2022.
Reason for Discontinuation:
Discontinued by Vendor
Cryptosporidium & Giardia Antigens by EIA (OVAPSC)
Effective April 14, 2022.
Specimens submitted for A1APHE testing will be stored frozen while reagents are unavailable; stability is three months.
ARUP Laboratories anticipates testing to resume in late May and will complete the backlog of specimens as soon as possible.
April 7, 2022: Digoxin, Free, Serum (DIGFR) testing has resumed, and DIGFR ordering has been re-enabled.
For more information, please contact Client Services for assistance.
Effective February 28, 2022.
Any new DIGFR orders placed after February 28, 2022 will be canceled.
Cleveland Clinic Laboratories will provide an update when Digoxin, Free, Serum testing is available again.
Effective December 14, 2021.
HIV-1 by Western Blot (HIV1CO) testing performed by CCL’s partnered reference laboratory is experiencing extended test delays caused by a nationwide shortage of testing kits.
These delays are anticipated to affect HIV1CO testing until February 2022.
Test name:
HIV-1/2 Ab Confirmatory
Order code:
HIV12M
Specimen type:
Serum
Collection container:
Gold Serum Separation Tube (SST)
Alternative specimen type:
Plasma
Alternative collection container:
Lavender K2EDTA Tube
Transport temperature:
Refrigerated
Refer to the details provided below for further information.
Effective October 25, 2021.
Original Communication:
Beginning October 25, 2021, Testosterone, Total and Free, Serum (TFTEST) will be temporarily sent to an alternate reference laboratory (Quest Diagnostics).
This will occur automatically for new TFTEST samples received by Cleveland Clinic Laboratories.
Methodology
The assays performed by both reference laboratories employ the same method, but there will be two main changes to the results:
1. Units of reporting for free testosterone will change from ng/dL to pg/mL.
Conversion factors:
2. Reference intervals for both free and total testosterone will be different.
Age
0-1 day
1-10 days
11-30 days
31 days – 2 months
3-4 months
5-6 months
7-11 months
12 months – 5 years
6-7 years
8-10 years
11 years
12-13 years
14-17 years
> 17 years
Male
17-61
<188
Not given
72-344
<202
<60
<17
<6
<26
<43
<261
<421
<1001
250-1100
Female
16-44
<25
Not given
<18
<13
<14
<12
<9
<21
<36
<41
<41
<41
2-45
Age
0-4 years
5-9 years
10-13 years
14-17 years
18-69 years
70-89 years
>89 years
Male
Not given
<5.4
0.7-52.0
18.0-111.0
35.0-155.0
30.0-135.0
Not given
Female
Not given
0.2-5.0
0.1-7.4
0.5-3.9
0.1-6.4
0.2-3.7
Not given
Specimen Type
Serum
Collection Container
Red BD Hemogard™ Serum Tube (No Additive)
Volume
1.8 mL
Minimum Volume
0.9 mL
Do not draw serum gel tubes for this test.
Turnaround Time
Turnaround time for samples sent to the temporary performing laboratory (Quest Diagnostics) is estimated at 10 to 14 days.
TFTEST samples collected prior to October 25 will be resulted from the current reference laboratory (Mayo Medical Laboratories) but will have a delayed turnaround time of approximately 14 days.
Effective July 1, 2021.
Due to vendor reagent being on backorder, Hepatitis A Antibody, Total (AHAVT)’s initially scheduled discontinuation on August 7 has been expedited to July 1, 2021.
AHAVG Clinical Info:
Determines immune status to Hepatitis A Virus (HAV) as a result of vaccination or past infection. Should a recent infection be suspected, this test needs to be ordered with AHAVM.
AHAVM Clinical Info:
Assesses acute or recent HAV infection. Note: Methodology not approved for donor testing.
This test is no longer offered by the performing reference laboratory.
At this time, there is no recommended replacement test.
While supplies are constrained, culture and antigen testing will be used in place of PCR testing to interrogate specimens for the same pathogens as STLPCR: Campylobacter, Salmonella, Shigella, and Shiga toxin-producing E. coli (STEC/EHEC).
Cleveland Clinic Laboratories will temporarily cancel and credit any STLPCR test requests, then substitute clinically-equivalent culture and antigen testing.
The associated CPT codes for these substitutions are:
• 87449 (x 2)
• 87045
Effective March 22, 2019.
Effective immediately, 14-3-3 Protein, CSF (PR1433) is discontinued with no recommended replacement.
The performing laboratory is evaluating new reagents; if these are found to be acceptable, this test may be reactivated in the future.
Effective April 18, 2019.
Ganglioside Antibody Panel (GM1BM) will be discontinued on April 18, 2019.
We suggest ordering Ganglioside Antibodies (GANGAB).
Effective April 22, 2019.
Changes to Reference Ranges
OmegaCheck:
> 5.4% by wt
Arachidonic Acid/EPA Ratio:
3.7 – 40.7
Omega-6/3 Ratio:
3.7 – 14.4
EPA:
0.2 – 2.3% by wt
DPA:
0.8 – 1.8% by wt
DHA:
1.4 – 5.1% by wt
Arachidonic Acid:
8.6 – 15.6% by wt
Linoleic Acid:
18.6 – 29.5% by wt
Any additional information will be included in a future Technical Update. If you have any questions about these changes, please contact Client Services for assistance.
Effective March 6, 2019.
Volume:
0.5 mL, serum
Minimum Volume:
0.35 mL, serum
Collection Container:
Red BD Hemogard™ Serum Tube (No Additive)
Plasma is no longer an acceptable specimen type.
Serum from a gel tube remains unacceptable.
Specimen Instructions:
Draw specimen immediately before the next scheduled dose. Trough specimens are recommended, as therapeutic ranges are based on trough collections.
Centrifuge the specimen within two hours of collection, transfer the serum into a standard plastic aliquot tube, and transport refrigerated.
Transport Temperature:
Refrigerated
Any additional information will be included in a future Technical Update. If you have any questions about these changes, please contact Client Services for assistance.
